The aesthetics trade is present process a serious shift, largely fueled by the rise of GLP-1 medicines. These remedies at the moment are enjoying a pivotal function in reshaping what sufferers are having accomplished whereas boosting aesthetic practices. In 2024, the $17.5 billion aesthetics trade skilled a 2 p.c total development, with remedies like Ozempic, Wegovy and Zepbound driving a formidable 11 p.c surge in spending within the nonsurgical class.
In line with the numbers, spending on neurotoxin remedies was up 4 p.c, and common affected person spend rose to $1,471. “GLP-1s are rewriting the playbook for medical aesthetics,” says Erik Haines, managing director at Guidepoint Qsight, an information and analytics agency specializing in healthcare tendencies. “Not solely are they producing vital income, however they’re additionally attracting a brand new wave of sufferers—40 p.c of whom had been first-timers in 2024.”
The info speaks volumes. Practices providing GLP-1 remedies reported a 9 p.c income improve, whereas people who didn’t noticed a 2 p.c decline. On common, GLP-1 remedies themselves now contribute 15 p.c of month-to-month income for taking part suppliers.
A Altering Demographic
In 2024, the report additionally finds that Gen Z sufferers accounted for 10 p.c of all aesthetics clientele—almost 3 times their presence in 2017. In the meantime, child boomers comprised simply 20 p.c of sufferers, underscoring a generational pivot towards nonsurgical remedies.
In line with survey outcomes, medspas are on the forefront of this variation, with 60 p.c providing GLP-1 providers in comparison with solely 35 p.c of aesthetic doctor workplaces. Because the demand for nonsurgical remedies grows, GLP-1 weight reduction successes have turn out to be a profitable alternative for practices aiming to draw new shoppers, giving the trade as a complete a lift.
